[Pulmonary edema during tocolytic treatment (author's transl)].
During tocolytic treatment with Beta 2-Sympathomimetic drugs pulmonary edema is occasionally observed. The cause remains uncertain. Within 48 hours after the onset of treatment marked water retention is observed. The weight increases, the hemoglobin decreases the hematocrit decreases, the albumin concentration decreases, the water and sodium excretion decreases. The pathogenesis is discussed and recommendations for the management are proposed. Water retention due to tocolytic treatment in addition to the physiologic water retention of pregnancy or in addition to pre-eclampsia cortisone treatment, renal insufficiency, or treatment with intravenous infusions may lead to a hypervolemia which can no longer be compensated by diuresis and therefore can lead to pulmonary edema. A list of 10 groups of patient with a high risk is described. These require thorough observation following tocolytic treatment.
D001798:Blood Proteins / Q000032:analysis; D001835:Body Weight; D004983:Ethanolamines / Q000009:adverse effects*; D005260:Female; D005280:Fenoterol / Q000009:adverse effects*; D006400:Hematocrit; D006454:Hemoglobins; D006801:Humans; D007752:Obstetric Labor, Premature / Q000517:prevention & control*; D011247:Pregnancy; D011654:Pulmonary Edema / Q000139:chemically induced*; D013997:Time Factors; D014700:Verapamil / Q000009:adverse effects*; D014867:Water
D001798:Blood Proteins; D004983:Ethanolamines; D006454:Hemoglobins; D014867:Water; D005280:Fenoterol; D014700:Verapamil
Zur Frage des Lungenödems bei der tokolytischen Therapie.